Previous 10 | Next 10 |
2024-01-30 08:30:28 ET More on Pre-market losers & stocks. Borr Drilling: Still Undervalued, But The Easy Money Has Already Been Made Borr Drilling: Jackup Market Expected To Remain Strong - Buy Borr Drilling Limited (BORR) Q3 2023 Earnings Call Transcript ...
2024-01-29 10:00:02 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...
2024-01-24 10:01:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-24 08:35:25 ET Nxu ( NXU ) +37% Showcasing Innovation and Leadership in EV Charging Technology. SciSparc ( SPRC ) +50% announces $20M standby equity purchase agreement. Kura Oncology ( KURA ) +35% announces oversubscribed $150 mi...
2024-01-21 16:50:33 ET More on Pacific Biosciences of California, AVITA Medical, etc. AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now Reassessing Pacific Biosciences: Deep...
Nyxoah Announces 2024 Strategic Priorities Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development ...
2024-01-10 06:33:38 ET Nyxoah ( NASDAQ: NYXH ) has expected Q4 revenue to be ~€1.8M, up 40% from the prior year and 87% sequentially. FY23 revenue is expected to be ~€4.3M, up 41% Y/Y. Ended the year with 48 active German accounts. “We are excited ...
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology ...
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr . Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Gui...
News, Short Squeeze, Breakout and More Instantly...
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the ...
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (&...
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the develop...